Neurocrine builds long-term case for Crenessity in congenital adrenal hyperplasia
See how Neurocrine’s two-year Crenessity data may reshape long-term classic CAH care, steroid reduction and pediatric outcomes.
Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability
Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.